SCHEMBL6852174

SCHEMBL6852174

O=C/C=C/c1cnc2ccccc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.48
NPC1 O15118 4/20 0.48
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
KDM4E B2RXH2 4/20 0.46
PAX8 Q06710 1/20 0.46
LMNA P02545 3/20 0.44
POLB P06746 1/20 0.44
THRB P10828 1/20 0.44
PIM1 P11309 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PDE10A Q9Y233 1/20 0.41
TRPA1 O75762 1/20 0.41
ALOX5 P09917 1/20 0.41
MAPK1 P28482 1/20 0.41
MAPT P10636 5/20 0.40
HTT P42858 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6852180 1.00 RAB9A (0.48) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL97699 0.80 ALDH1A1 (0.47) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL707786 0.80 PDGFRB (0.50) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL707785 0.80 PDGFRB (0.50) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
Hydrochloric Acid SCHEMBL28114264 0.79 ALDH1A1 (0.46) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL27991306 0.79 ALDH1A1 (0.46) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL28747408 0.79 ALDH1A1 (0.46) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7940364 0.77 RAB9A (0.50) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL6852218 0.77 RAB9A (0.50) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL12923109 0.77 PAX8 (0.63) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11161823-B2 Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof NATIONAL GUARD HEALTH AFFAIRS (SA) 2021-11-02 US disclosed
US-20200290975-A1 ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF NATIONAL GUARD HEALTH AFFAIRS (SA) 2020-09-17 US disclosed
CN-1585775-A 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials ORTHO MCNEIL PHARM INC (US) 2005-02-23 CN disclosed
US-6825170-B2 ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-11-30 US disclosed
EP-1453847-A1 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS Ortho-Mcneil Pharmaceutical, Inc. (US) 2004-09-08 EP disclosed
US-20030220272-A1 6-O-acyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-11-27 US disclosed
WO-2003050132-A1 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220272-A1 6-O-acyl ketolide antibacterials Q6ZSR9, ACSL6, RPS4Y1 RAB9A 982/4885NPC1 2962/4885ALDH1A1 2109/4885
US-11161823-B2 Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof PDK1, PDHA1, PDHA2 RAB9A 4241/4885NPC1 4120/4885ALDH1A1 7/4885
US-20200290975-A1 ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF PDK1, PDHA1, PDHA2 RAB9A 4241/4885NPC1 4120/4885ALDH1A1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.